专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09468599B2 Composition and method for compounded therapy 有权
标题翻译：复合治疗的组合物和方法
公开(公告)号：US09468599B2
公开(公告)日：2016-10-18
申请号：US13448088
申请日：2012-04-16
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/54 , A61K31/495 , A61K31/50 , A61K31/135 , A61K9/00 , A61K31/5415 , A61K31/167 , A61K31/53 , A61K31/7048 , A61K9/06
CPC分类号： A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/53 , A61K31/5415 , A61K31/7048 , A61K2300/00 , A61K31/63
摘要： The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
摘要翻译：本实施例涉及局部递送的复合药物。透皮霜可以同时提供多种药物的有效局部给药; 可以包括低浓度的局部麻醉剂，NSAID，抗惊厥药和/或其它活性成分; 并且可以包括利多卡因，丙胺卡因，美洛昔康和拉莫三嗪和/或托吡酯。或者，透皮霜可以包括利多卡因/丙胺卡因基础霜，其中加入一种或多种地面药物的细粉末以形成复合药物。粉末形式的复合药物可以通过研磨NSAIDs，抗惊厥药，神经抑制剂，抗抑郁药，肌肉松弛剂，NMDA受体拮抗剂，阿片剂或阿片样物质激动剂和/或其它药剂来产生。粉末形式的复合药物可以包括美洛昔康，拉莫三嗪，托吡酯，其他活性成分，和DMSO或无菌水用于灌溉。在另一方面，本实施方案涉及配制药物和透皮霜或凝胶的方法。

2. 发明申请

US20130085171A1 COMPOUNDED TRANSDERMAL PAIN MANAGEMENT 有权
标题翻译：化合物超声波治疗
公开(公告)号：US20130085171A1
公开(公告)日：2013-04-04
申请号：US13328369
申请日：2011-12-16
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/135 , A61K31/192 , A61P25/24 , A61P29/00 , A61P21/02 , A61P23/02 , A61K31/195 , A61K31/4168
CPC分类号： A61K31/135 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/192 , A61K31/195 , A61K31/197 , A61K31/4168 , A61K47/02 , A61K2300/00
摘要： The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application.
摘要翻译：本实施方案涉及用于治疗疼痛，炎症，肌肉疲劳，痉挛和/或其它疾病的局部递送药物（复合）。透皮霜可以同时提供多种药物的有效局部给药。透皮霜可以包括大约30％或更大的盐负荷。透皮霜可以包括独特的基础组合物，使得透皮霜可能能够保持稳定并且避免六个月或更长时间的降解，并能够有效递送超过总制剂重量的约40％或更多的活性成分浓度。活性成分可包括神经抑制剂，NSAID，肌肉松弛剂，阿片激动剂，局部麻醉剂，NMDA受体拮抗剂和三环类抗抑郁药。在一个实施方案中，透皮霜可包含氯胺酮HCL，加巴喷丁，可乐定HCL和巴氯芬。透皮霜可以通过单次透皮应用递送增强的氯胺酮局部输送通量。

3. 发明授权

US09592241B2 Silicone-based composition for skin treatment 有权
标题翻译：用于皮肤治疗的基于硅酮的组合物
公开(公告)号：US09592241B2
公开(公告)日：2017-03-14
申请号：US13564467
申请日：2012-08-01
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/56 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/695 , A61K9/00 , A61K47/24 , A61K9/06 , A61K47/34 , A61K45/06
CPC分类号： A61K47/34 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/24 , A61K2300/00
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.
摘要翻译：本实施方案可涉及用于治疗瘢痕组织，皮肤病症和/或其它疾病的局部递送的复合药物。一方面，透皮霜或凝胶可以同时提供多种药物的有效施用。优选地，可以提供基于硅氧烷的凝胶作为基础组合物，并且可以具有非零百分比的硅氧烷或硅氧烷变体。硅氧烷基凝胶可以包括环戊硅氧烷，聚硅氧烷-11，聚二甲基硅氧烷和C30-45烷基鲸蜡硬脂基聚二甲基硅氧烷交联聚合物，并且包括几种活性成分，例如糖皮质激素，抗组胺剂和神经抑制剂。硅氧烷基凝胶可以包括氟替卡松，氯雷他定和加巴喷丁的组合。氟替卡松和氯雷他定的浓度可能相对较低，而加巴喷丁的浓度中等程度较高。硅氧烷基凝胶还可以具有一种或多种局部麻醉剂，如丙卡因和/或利多卡因。硅氧烷基凝胶可以包括另外的活性成分，例如NSAID，抗惊厥药，抗抑郁药，肌肉松弛剂和/或其它活性成分。

4. 发明授权

US09724294B2 Composition and method for compounded therapy 有权
公开(公告)号：US09724294B2
公开(公告)日：2017-08-08
申请号：US13564525
申请日：2012-08-01
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/54 , A61K9/00 , A61K31/5415 , A61K31/167 , A61K31/53 , A61K31/7048 , A61K9/06
CPC分类号： A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/53 , A61K31/5415 , A61K31/7048 , A61K2300/00 , A61K31/63
摘要： The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.

5. 发明申请

US20130165420A1 SILICONE-BASED COMPOSITION FOR SKIN TREATMENT 有权
公开(公告)号：US20130165420A1
公开(公告)日：2013-06-27
申请号：US13564467
申请日：2012-08-01
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/56 , A61P17/02 , A61K31/569
CPC分类号： A61K47/34 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/195 , A61K31/4545 , A61K31/56 , A61K31/695 , A61K45/06 , A61K47/10 , A61K47/22 , A61K47/24 , A61K2300/00
摘要： The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.

6. 发明授权

US09724315B2 Compounded transdermal pain management 有权
公开(公告)号：US09724315B2
公开(公告)日：2017-08-08
申请号：US13328369
申请日：2011-12-16
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/135 , A61K31/192 , A61K31/195 , A61K31/4168 , A61K31/167 , A61K31/197 , A61K9/00 , A61K47/02 , A61K9/06
CPC分类号： A61K31/135 , A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/192 , A61K31/195 , A61K31/197 , A61K31/4168 , A61K47/02 , A61K2300/00
摘要： The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application.

7. 发明申请

US20130165430A1 COMPOSITION AND METHOD FOR COMPOUNDED THERAPY 有权
标题翻译：用于复合治疗的组合物和方法
公开(公告)号：US20130165430A1
公开(公告)日：2013-06-27
申请号：US13564525
申请日：2012-08-01
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/5415 , A61P21/02 , A61P25/00 , A61P29/00 , A61P25/08
CPC分类号： A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/53 , A61K31/5415 , A61K31/7048 , A61K2300/00 , A61K31/63
摘要： The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
摘要翻译：本实施例涉及局部递送的复合药物。透皮霜可以同时提供多种药物的有效局部给药。透皮霜可以包括低浓度的局部麻醉剂，NSAID，抗惊厥药和/或其它活性成分。例如，透皮霜可以包括利多卡因，丙胺卡因，美洛昔康和拉莫三嗪和/或托吡酯。或者，透皮霜可以包括利多卡因/丙胺卡因基础霜，其中加入一种或多种地面药物的细粉末以形成复合药物。粉末形式的复合药物可以通过研磨NSAIDs，抗惊厥药，神经抑制剂，抗抑郁药，肌肉松弛剂，NMDA受体拮抗剂，阿片剂或阿片样物质激动剂和/或其它药剂来产生。粉末形式的复合药物可以包括美洛昔康，拉莫三嗪，托吡酯和/或其它活性成分。在另一方面，本实施方案涉及配制药物和透皮霜或凝胶的方法。

8. 发明申请

US20130165429A1 COMPOSITION AND METHOD FOR COMPOUNDED THERAPY 有权
标题翻译：用于复合治疗的组合物和方法
公开(公告)号：US20130165429A1
公开(公告)日：2013-06-27
申请号：US13448088
申请日：2012-04-16
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/5415 , A61P21/02 , A61P25/24 , A61P29/00 , A61P25/08
CPC分类号： A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/53 , A61K31/5415 , A61K31/7048 , A61K2300/00 , A61K31/63
摘要： The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
摘要翻译：本实施例涉及局部递送的复合药物。透皮霜可以同时提供多种药物的有效局部给药; 可以包括低浓度的局部麻醉剂，NSAID，抗惊厥药和/或其它活性成分; 并且可以包括利多卡因，丙胺卡因，美洛昔康和拉莫三嗪和/或托吡酯。或者，透皮霜可以包括利多卡因/丙胺卡因基础霜，其中加入一种或多种地面药物的细粉末以形成复合药物。粉末形式的复合药物可以通过研磨NSAIDs，抗惊厥药，神经抑制剂，抗抑郁药，肌肉松弛剂，NMDA受体拮抗剂，阿片剂或阿片样物质激动剂和/或其它药剂来产生。粉末形式的复合药物可以包括美洛昔康，拉莫三嗪，托吡酯，其他活性成分，和DMSO或无菌水用于灌溉。在另一方面，本实施方案涉及配制药物和透皮霜或凝胶的方法。

9. 发明授权

US08327610B1 Capsule opener and emptier 有权
标题翻译：胶囊开瓶器和清洁剂
公开(公告)号：US08327610B1
公开(公告)日：2012-12-11
申请号：US13564391
申请日：2012-08-01
申请人： Jay Richard Ray, II
发明人： Jay Richard Ray, II
IPC分类号： B67B7/00
CPC分类号： B65B69/00 , A61M15/0036 , A61M2202/064 , B65B69/0041
摘要： The present embodiments are directed to a medicinal extractor that may open and empty pharmaceutical capsules of variable sizes. The medicinal extractor may have a cover that swings open to expose an interior chamber for a powder-filled medication capsule to be dropped into, and the cover may then be closed. The medicinal extractor may have squeezable side depressors on each side for manually squeezing or holding the capsule in place horizontally. Once closed, the cover may be pushed down to compress two components of the medicinal extractor that are moveable with respect to each other. As the moveable components compress, the cover may press the capsule downward onto a hollow piercing element. The hollow piercing element may puncture the capsule to allow medication within the capsule to fall through the hollow piercing element and into a collection chamber or onto a surface below the medicinal extractor for collection.
摘要翻译：本实施例涉及可以打开和清空可变尺寸的药物胶囊的药用提取器。药用提取器可以具有打开的盖子，以露出用于粉末填充的药物胶囊的内部腔室，并且盖子然后可以被关闭。药用提取器可以在每侧具有可挤压侧压，用于手动挤压或将胶囊保持在水平位置。一旦关闭，可以将盖子推下来压缩可相对于彼此移动的药物提取器的两个部件。当可移动部件压缩时，盖可以将胶囊向下压到中空穿刺元件上。中空穿刺元件可以刺穿胶囊，以允许胶囊内的药物通过中空穿刺元件落入收集室或药物提取器下方的表面以便收集。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式